

carbidopa/levodopa extended-release capsule (RYTARY)

Diagnoses Considered for Coverage:

- Parkinson's disease
- Post-encephalitic parkinsonism
- Parkinsonism that may follow carbon monoxide intoxication or manganese intoxication

Coverage Criteria:

For diagnosis listed above:

- Dose does not exceed FDA label maximum, **and**
- Patient unable to use generically available extended-release carbidopa/levodopa

Coverage Duration: one year

References:

1. Rytary prescribing information. Amneal Specialty. Bridgewater, NJ. 12/2022

Effective Date: 11/02/2023